HISTORY

Myogem Health Company S.L. is a spanish healthcare company located in Mollet del Vallés, Barcelona, SPAIN.

The company is a Spin-off of Inkemia IUCT Group, that focuses its attention on R&D and commercialization of new products against Rare Diseases.

Rare diseases have always been treated in a quite different way respect to the rest of the illness, because of the narrow range of company disposed to invest on them and the little attention they receive from the media, the intent of Myogem Health Company is offering to the patients affected by these disease a possibility to have better life through a range of products that aim to improve their health condition and quality of their lives.

CTGEN

Everything started back in 2007 when Inkemia IUCT Group first started its research in Myotonic Dystrophy with a project called “New therapeutic Approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies”, a CTGEN Project, funded by the Genome Spain Foundation, during which no exploitable results were obtained.

New therapeutic Approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies

Project coordinators:

  • Universidad de Valencia. Departamento de Genética (GENÉTICA‐UV)
  • Universidad de Valencia. Departamento de Genética (UCIM-UV)
  • Centro de Biología Molecular Severo Ochoa (CBMSO)
  • Valentia Biopharma (VLT)
  • Instituto Biomar (BIOMAR)
  • Institut Univ. de Ciència i Tecnologia (IUCT)
  • Sistemas Genómicos (SG)
  • Centro de Investigación Príncipe Felipe (CIPF)

Fund: 900.000 €

lamaratò

The next project happened in 2009, thanks to the participation in a project called “La Marató de TV3“. That edition was particularly focused on fundraising projects that pretended to advance the prevention, diagnosis, prognosis and treatment of Rare Diseases.

During that edition more than 287 projects were presented but according to the proposal of the Scientific Advisory Committee of the Fundació La Marató de TV3, just 20 Research projects of excellence have been selected and funded with a total amount of 6.350.999 €.

Among which, our project, named “Development of new treatments for Myotonic Dystrophy: discovery of drugs in vivo, was conducted thanks to the collaboration among three important Institutions.

Inkemia IUCT group, under the supervision of Dr. Josep Castells, The University of Valencia (Faculty of Biological Sciences) represented by the Coordinatoor of the whole project Dr. Rubén Artero and the IQS (Institut Quimic de Sarriá) represented by the Dr. José I. Borrell and Dr. Jordi Teixidó.

Among the libraries we have been screening and the work that followed, the main results that were obtained which showcased the best activity either in vitro (in DM1 patient’s myoblasts) and in vivo (in Drosophila models), were divided in three different kinds regarding their nature, properties and development strategy: Natural Products – Repositioning Drugs – Rationally Designed New Compounds.

This way, it has been possible to apply for two European patents related to Hit IUCT 309 and TFL 1-2  and the possibility to apply for new patents in order to protect the development of additional hits is under evaluation.

Development of new treatments for myotonic dystrophy: discovery of drugs in vivo

Project coordinators:

  • Dr. Rubén Darío Artero Allepuz
    Facultat de Ciències Biològiques UV
  • Dr. José Ignacio Borrell Bilbao
    Institut Químic de Sarrià URL
  • Dr. Josep Castells Boliart
    Institut Universitari de Ciència i Tecnologia. Mollet
Fund: 376.820 €

MYODM1

Because of those promising results it was decided to keep researching and, at the beginning of 2015, one of our projects with the acronym Myo-DM1 got the approval for a competitive program, PID of CDTI. This project’s title is “Development of food supplements to improve the quality of life of patients suffering from Myotonic Distrophy type 1 (DM1)” and has a duration of approximately 2 years (2015-2017).

To give continuity to these results, InKemia IUCT Group has agreed to license the obtained discoveries in this project to its spin-off Myogem Health Company S.L. so it can put them to the reach of people affected by Myotonic Distrophy.

Development of food supplements to improve the quality of life of patients suffering from Myotonic Distrophy type 1 (DM1)

Project coordinators:

  • Dr. Josep Castells Boliart
    Institut Universitari de Ciència i Tecnologia. Mollet
  • Marta Pascual Gilabert

    Institut Universitari de Ciència i Tecnologia. Mollet
  • Dr. Rubén Darío Artero Allepuz
    Facultat de Ciències Biològiques UV

Fund: 494.158 €

Myogem Health Company was established by a mix of biologist, biotechnologists, chemists and pharmacists, brought together with the common purpose of reach this unmet medical need.

From our studies and working experiences we have become experts in the field of Healthcare and Life Science and after several years in research we know how to offer the best products, in the other hand thanks to years hard work we have the expertise of our commercial branch by our side leading us through the market.